<?xml version="1.0"?>
<oembed><version>1.0</version><provider_name>Achucarro Basque Center for Neuroscience</provider_name><provider_url>https://www.achucarro.org/eu/</provider_url><title>Modulation of Parkinson's disease LRRK2 activity and pathogenicity - Achucarro Basque Center for Neuroscience</title><type>rich</type><width>600</width><height>338</height><html>&lt;blockquote class="wp-embedded-content" data-secret="7pUx1jRp6g"&gt;&lt;a href="https://www.achucarro.org/eu/mintegia/2019-02-iban-ubarretxena/"&gt;Modulation of Parkinson&#x2019;s disease LRRK2 activity and pathogenicity&lt;/a&gt;&lt;/blockquote&gt;&lt;iframe sandbox="allow-scripts" security="restricted" src="https://www.achucarro.org/eu/mintegia/2019-02-iban-ubarretxena/embed/#?secret=7pUx1jRp6g" width="600" height="338" title="&#x201C;Modulation of Parkinson&#x2019;s disease LRRK2 activity and pathogenicity&#x201D; &#x2014; Achucarro Basque Center for Neuroscience" data-secret="7pUx1jRp6g" frameborder="0" marginwidth="0" marginheight="0" scrolling="no" class="wp-embedded-content"&gt;&lt;/iframe&gt;&lt;script&gt;
/*! This file is auto-generated */
!function(d,l){"use strict";l.querySelector&amp;&amp;d.addEventListener&amp;&amp;"undefined"!=typeof URL&amp;&amp;(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&amp;&amp;!/[^a-zA-Z0-9]/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret="'+t.secret+'"]'),o=l.querySelectorAll('blockquote[data-secret="'+t.secret+'"]'),c=new RegExp("^https?:$","i"),i=0;i&lt;o.length;i++)o[i].style.display="none";for(i=0;i&lt;a.length;i++)s=a[i],e.source===s.contentWindow&amp;&amp;(s.removeAttribute("style"),"height"===t.message?(1e3&lt;(r=parseInt(t.value,10))?r=1e3:~~r&lt;200&amp;&amp;(r=200),s.height=r):"link"===t.message&amp;&amp;(r=new URL(s.getAttribute("src")),n=new URL(t.value),c.test(n.protocol))&amp;&amp;n.host===r.host&amp;&amp;l.activeElement===s&amp;&amp;(d.top.location.href=t.value))}},d.addEventListener("message",d.wp.receiveEmbedMessage,!1),l.addEventListener("DOMContentLoaded",function(){for(var e,t,s=l.querySelectorAll("iframe.wp-embedded-content"),r=0;r&lt;s.length;r++)(t=(e=s[r]).getAttribute("data-secret"))||(t=Math.random().toString(36).substring(2,12),e.src+="#?secret="+t,e.setAttribute("data-secret",t)),e.contentWindow.postMessage({message:"ready",secret:t},"*")},!1)))}(window,document);
//# sourceURL=https://www.achucarro.org/wp-includes/js/wp-embed.min.js
&lt;/script&gt;
</html><description>Missense mutations in Leucine-Rich Repeat Kinase 2 (LRRK2) cause the majority of familial and some sporadic forms of Parkinson&#x2019;s disease (PD). LRRK2 kinase hyperactivity underlies the pathogenicity of these mutations, and thus inhibition of this enzyme holds promise for the treatment of PD. Potent and specific LRRK2 kinase inhibitors have been reported; however, their safety [&hellip;]</description></oembed>
